# Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients

> **NCT06575530** · PHASE4 · RECRUITING · sponsor: **Beijing Shijitan Hospital, Capital Medical University** · enrollment: 306 (estimated)

## Conditions studied

- Effect of Drug
- Adverse Drug Event
- Mechanical Ventilation Complication
- Critical Illness
- Surgery
- Sedation

## Interventions

- **DRUG:** Remimazolam Besylate
- **DRUG:** Dexmedetomidine Hydrochloride

## Key facts

- **NCT ID:** NCT06575530
- **Lead sponsor:** Beijing Shijitan Hospital, Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2026-04-20
- **Final completion:** 2026-06-20
- **Target enrollment:** 306 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06575530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06575530, "Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06575530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*